Building molecular 'cages' to fight disease

ScienceDaily (May 31, 2012) UCLA biochemists have designed specialized proteins that assemble themselves to form tiny molecular cages hundreds of times smaller than a single cell. The creation of these miniature structures may be the first step toward developing new methods of drug delivery or even designing artificial vaccines.

"This is the first decisive demonstration of an approach that can be used to combine protein molecules together to create a whole array of nanoscale materials," said Todd Yeates, a UCLA professor of chemistry and biochemistry and a member of the UCLA-DOE Institute of Genomics and Proteomics and the California NanoSystems Institute at UCLA.

Published June 1 in the journal Science, the research could be utilized to create cages from any number of different proteins, with potential applications across the fields of medicine and molecular biology.

UCLA graduate student Yen-Ting Lai, lead author of the study, used computer models to identify two proteins that could be combined to form perfectly shaped three-dimensional puzzle pieces. Twelve of these specialized pieces fit together to create a molecular cage a mere fraction of the size of a virus.

"If you just connect two random proteins together, you expect to get an irregular network," said Yeates, senior author of the study. "In order to control the geometry, the idea was to make a rigid link holding the two proteins in place as if they were parts of a toy puzzle."

The specifically designed proteins intermesh to form a hollow lattice that could act as a vessel for drug delivery, he said.

"In principle, it would be possible to attach a recognition sequence for cancer cells on the outside of the cage, with a toxin or some other 'magic bullet' contained inside," said Yeates. "That way, the drug could be delivered directly to certain targets like tumor cells."

At this stage, the assembled protein cages are porous enough that a drug placed inside would likely leak out during the delivery process, Lai said. His next project will involve constructing a new molecular cage with an interior that will be better sealed.

Another use for the versatile protein structures might be as artificial vaccines. Some traditional vaccines use an inactive surface protein from a virus to trick the body's immune system into thinking it is under attack. This method isn't always effective, because sometimes the protein in question doesn't look enough like the virus to trigger a strong response from the body's defenders.

However, by decorating the surface of a molecular cage with segments of virus-derived proteins, the tiny structures might better mimic a virus, stimulating an immune response even stronger than a traditional vaccine and better protecting the human recipient from illness.

Read the rest here:

Building molecular 'cages' to fight disease

NanoString Technologies Names Bruce Seeley Senior Vice President & General Manager, Diagnostics

SEATTLE--(BUSINESS WIRE)--

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the appointment of Bruce J. Seeley as Senior Vice President & General Manager, Diagnostics. In this role, Mr. Seeley will have responsibility for providing strategic direction and commercial leadership for NanoStrings newly formed Diagnostics business, including the global launch of its genomic test for breast cancer based on the PAM50 gene signature following regulatory clearance.

Mr. Seeley joins NanoString with more than 20 years of U.S. and global oncology-focused experience. Most recently, he was Executive Vice President, Commercial at Seattle Genetics, where he built and led the commercial organization and successfully launched the companys first product: ADCETRIS, a targeted therapy for lymphoma. Before joining Seattle Genetics in 2009 he worked for Genentech (a wholly owned member of the Roche Group), most recently as Senior Director, Marketing, HER2 Brands, where he led the launch of HERCEPTIN in adjuvant breast cancer. From 2000 to 2004, Mr. Seeley worked for Aventis Pharma in increasing roles of responsibility, including Senior Director of New Product Commercialization and Licensing, Global Marketing, Oncology. Previously, he held various marketing and sales positions at Rhone-Poulenc Rorer and Bristol-Myers Squibb.

Mr. Seeley commented: Ive dedicated my career to delivering high-impact products that improve the lives of cancer patients. It is clear that molecular diagnostics will continue to play an increasingly pivotal role in driving newer and more effective treatments for cancer. I'm looking forward to applying the experience I gained commercializing targeted therapeutics toward ushering in a new era of personalized medicine enabled by in vitro diagnostics based on NanoString's powerful nCounter technology.

With this appointment, we are formalizing our commitment to building two synergistic businesses based on our nCounter Analysis System, said Brad Gray, President and CEO of NanoString Technologies. Our Life Sciences business has grown rapidly under Barney Saunders commercial leadership, and will now benefit even more strongly from his increased focus. Bruce's skills and experience perfectly match our objective of commercializing diagnostics that inform major decisions in the treatment of cancer, beginning with our PAM50-based breast cancer assay.

NanoString recently initiated its second clinical validation study for the PAM50 breast cancer assay, which will evaluate samples from more than 1,000 patients enrolled in the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG8). Positive results from NanoStrings first clinical validation study were presented last December by the studys independent investigators at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The study, which included more than 1,000 samples from the TransATAC study of postmenopausal women with hormone receptor-positive early-stage breast cancer (ESBC), met all primary and secondary objectives.

The nCounter platform is currently available for Research Use Only. NanoStrings PAM50-based breast cancer assay is not currently available for use in diagnostic procedures.

More information is available at http://www.NanoString.com.

About NanoString Technologies, Inc.

NanoString Technologies is a privately held provider of life science tools for translational research and developer of molecular diagnostics. The companys nCounter Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The companys technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.

Read this article:

NanoString Technologies Names Bruce Seeley Senior Vice President & General Manager, Diagnostics

Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American …

AMSTERDAM and IRVINE, Calif., May 29, 2012 /PRNewswire/ --Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, announced today that it will present nine posters on genomic research studies in breast and colon cancer at the Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held from June 1-5, 2012, at McCormick Place in Chicago, IL.

Currently on the market in the U.S. and Europe, Agendia's Symphony suite of molecular diagnostic breast cancer tests enables physicians to determine whether a given breast cancer patient is likely to benefit from hormonal therapy, chemotherapy and targeted therapies, thereby providing benefits over existing treatment approaches for patients, physicians and payers.

Agendia's lead product, MammaPrint, is the first and only diagnostic breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). Agendia's product development pipeline includes a further extension of its breast cancer tests as well as similar molecular diagnostic products for colon cancer.

All of the abstracts listed below can currently be found online at http://www.ASCO.org. Presentation details are as follows (all times are in Central Time).

Friday, June 1, 2012

Colorectal Cancer

1. Poster Presentation & Discussion: Validation of a genomic classifier (ColoPrint) for predicting outcome in the T3-MSS subgroup of stage II colon cancer patients.

Saturday, June 2, 2012

Breast Cancer

2. Poster Presentation: Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in 180 U.S. breast cancer (BC) patients.

Read the original here:

Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American ...

UC San Diego Scientists Net $12 Million For Stem Cell Research

Five UC San Diego scientists have received almost $12 million combined from the California Institute for Regenerative Medicine to pay for stem cell-based research, the university announced today.

A team led by Lawrence Goldstein, of the Department of Cellular and Molecular Medicine and director of the UC San Diego Stem Cell Program, was given $1.8 million to continue looking for new methods to find and test possible medications for Alzheimer's disease, according to UCSD. They use reprogrammed stem cells in their work.

Dr. Mark Tuszynski, professor of neurosciences and director of the Center for Neural Repair, received $4.6 million to develop more potent stem cell-based treatments for spinal cord injuries.

Gene Yeo, assistant professor in the Department of Cellular and Molecular Medicine, was awarded $1.6 million to continue research into treatments for amyotrophic lateral sclerosis. His research hopes to take advantage of recent discoveries about ALS, or Lou Gehrig's disease, which center on mutations in RNA-binding proteins that cause dysfunction and death in neurons.

Dr. Eric David Adler, an associate clinical professor of medicine and cardiologist, was granted $1.7 million to screen potential drugs for Danon disease, a type of inherited heart failure that frequently kills patients by their 20s.

Yang Xu, a professor in the Division of Biological Sciences, was given $1.8 million to research the use of human embryonic stem cells to produce a renewable source of heart muscle cells that replace cells damaged or destroyed by disease, while overcoming biological resistance to new cells.

"With these new awards, the (institute) now has 52 projects in 33 diseases at varying stages of working toward clinical trials,'' said Jonathan Thomas, chairman of the CIRM governing board. "Californians should take pride in being at the center of this worldwide research leading toward new cures.''

CIRM was established in November 2004 with voter passage of the California Stem Cell Research and Cures Act. UC San Diego has received $112 million since CIRM began providing grants six years ago.

Read the rest here:

UC San Diego Scientists Net $12 Million For Stem Cell Research

Bayer HealthCare to Exhibit Innovative Device Technologies at 2012 SNM Annual Meeting

TARRYTOWN, N.Y., May 24, 2012 /PRNewswire/ --Bayer Radiology & Interventional will showcase new device technologies at the Annual Meeting of the Society of Nuclear Medicine (SNM) in Miami, June 9-13. The new technology includes enhancements to the Intego PET Infusion System, as well as developing platforms for controlled administration of molecular agents for SPECT and small animal imaging procedures.

In PET, the MEDRAD Intego System is a worldwide market leader and the only FDA cleared system for administration of 18F-FDG and 18F-NaF. Bayer has continued to innovate and evolve the Intego platform since its launch in 2008, including adding software features, expanding compatibility and indications, and significantly reducing the size of the device. At SNM, Bayer plans to demonstrate Certegra informatics solutions for Intego, including wireless integration to HIS/RIS/PACS systems which facilitate downloading the PET modality worklist as an infusion schedule and sending infusion results to PACS. This new capability will replace several manual processes, which in turn will streamline workflow and improve efficiency for PET imaging clinics.

Doug Descalzi, Bayer Sr. Director of Molecular Imaging Devices said, "Automated, controlled injection of molecular agents not only has safety and workflow benefits for staff, it can lead to improvements in patient care and help clinicians and scientists unlock the potential of molecular medicine."

In addition, in a scientific exhibition, the company will showcase developing technologies for controlled administration of low energy radiopharmaceuticals and for small animal molecular imaging. Both platforms demonstrate Bayer innovation and commitment to controlled administration technology.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at http://www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

See original here:

Bayer HealthCare to Exhibit Innovative Device Technologies at 2012 SNM Annual Meeting

Caris Target Now™ Data to be Showcased at ASCO 2012

IRVING, Texas, May 21, 2012 /PRNewswire/ --Caris Life Sciences, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced that eight data presentations on Caris Target Now, the foremost evidence-based molecular profiling service, will take place next month at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill.

One of the most widely used and innovative theranostic (i.e., therapeutic and diagnostic) tools available to oncologists, Caris Target Now is a service that interrogates a patient's tumor in all phases of the biologic process. Through analysis with multiple, highly integrated technology platforms, Caris Target Now provides information that is potentially vital for individualizing therapeutic regimens for cancer patients. By utilizing the latest molecular profiling technologies to determine the biomarkers unique to a patient's tumor, and by performing an extensive review of clinical literature correlating biomarkers to drug response, Caris Target Now can help illuminate the potential benefit (or lack thereof) of specific agents, and may reveal appropriate treatments not previously considered.

"As more is learned about the roles of various oncogenes, hormones, and proteins in the growth and proliferation of specific tumor types, it becomes increasingly important to individualize anticancer therapy based on the genetic profile of a patient's tumor," said Sandeep Reddy, MD, clinical professor of medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). "Consequently, tumor-specific genomic sequencing and analysis is quickly becoming the standard of care in oncology, rather than a last-resort option for when all other alternatives have been exhausted. The 2012 ASCO annual meeting therefore marks an important moment in molecular profiling, as eight separate presentations will add to the growing body of data supporting the use of Caris Target Now as a tool to help oncologists make evidence-based decisions for their patients."

The ASCO meeting will feature the following Caris Target Now data presentations:

Saturday, June 2, 2012

Monday, June 4, 2012

E-publications on http://www.jco.org

"The data to be presented at ASCO underscore how biomarkers can clear up much of the ambiguity oncologists face when making treatment decisions," commented Tom Spalding, group head of oncology at Caris Life Sciences. "By combining state-of-the-art molecular diagnostic and genomic sequencing technologies with a rigorous review of more than 100,000 published manuscripts, we believe Caris Target Now helps to expedite the evolution and accessibility of personalized medicine to cancer patients and their physicians."

About Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on developing and delivering innovative molecular diagnostic, prognostic, and theranostic services. The company's evidence-based molecular profiling service, Caris Target Now, matches molecular data generated from a patient's tumor with biomarker/drug associations derived from the world's leading clinical cancer literature. Caris Target Now uses the most advanced and clinically relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company's proprietary Carisome platform a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Through the precise and personalized information provided by technologies like Caris Target Now and Carisome, the company believes that the quality of healthcare can be dramatically improved, while also significantly reducing costs. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit http://www.carislifesciences.com or http://www.caristargetnow.com.

Continued here:

Caris Target Now™ Data to be Showcased at ASCO 2012

Distinct molecular subtype of prostate cancer discovered

ScienceDaily (May 20, 2012) A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers at Weill Cornell Medical College, the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute.

In the study, published online May 20 by the journal Nature Genetics, investigators describe how they discovered novel mutations in the SPOP ("S-pop") gene in numerous patient tumors, saying this alteration is thus far unique to prostate cancer and so represents a distinct molecular class that might assist in cancer diagnosis and treatment. Researchers suspect the mutations alter the way cells tag proteins for degradation, leading to an accumulation of dangerous molecules that drive the growth of cancer, perhaps from the beginning.

This finding adds to a string of discovery of other genes linked to prostate cancer over the years by this team of investigators, the totality of which is painting a comprehensive picture of how genetic alterations contribute to prostate cancer -- the most common cancer in men aside from skin cancer, accounting for the second leading cause of cancer deaths.

"These studies constitute a unique, meticulous and intensive look at prostate cancer to see the mechanisms driving this disease," says Dr. Mark A. Rubin, The Homer T. Hirst Professor of Oncology in Pathology and vice chair for experimental pathology at Weill Cornell Medical College. "This study, and our prior findings, tells us that prostate cancer is not just one disease. So far, we have found two main pathways for prostate cancer to develop and this opens the door to development of specialized diagnostic tools and treatments."

Mutations in SPOP constitute one major pathway, accounting for up to 15 percent of prostate cancer cases. The other is the 50 percent of prostate cancers containing the so-called "ETS" fusion genes, such as TMPRSS2-ERG.

"While there is still a need for increased discovery, it does appear that the overall genetic landscape of prostate cancer is taking shape, and better understanding of the biology and possible therapeutic avenues linked to these alterations has become a very high priority," says Dr. Levi Garraway, a senior associate member of the Broad Institute of MIT and Harvard, and assistant professor at the Dana-Farber Cancer Institute and Harvard Medical School.

Dr. Rubin and Dr. Garraway are co-senior investigators for this study and for others that have preceded it in this unique examination of prostate cancer genes.

In February 2011, the collaborative groups published a study in Nature in which they used whole genome sequencing to discern global changes and patterns of abnormality in seven prostate tumors and compared them to normal tissue samples. They found that areas of the genome had been unexpectedly rearranged -- just as Dr. Rubin and his collaborators at the University of Michigan had in 2005 with the discovery of the common recurrent TMPRSS2-ERG gene rearrangement, created by the fusion of two different genes.

This current study looked at different drivers of cancer, which are mutations in specific genes. It focused on the 1-2 percent of DNA in the genome that codes for proteins, and, as such, is one of the largest "whole exome" sequencing studies published on prostate cancer to date, according to Dr. Garraway.

The impetus to search for genes in this way came about because of the observation that SPOP appeared to be mutated in some cases of prostate cancer, says Dr. Christopher Barbieri, a fifth year urology resident at Weill Cornell who spent a research year in Dr. Rubin's laboratory in the Department of Pathology and Laboratory Medicine.

See the original post:

Distinct molecular subtype of prostate cancer discovered

Finnish researchers identified the cause for LGL leukemia

Public release date: 16-May-2012 [ | E-mail | Share ]

Contact: Dr. Satu Mustjoki satu.mustjoki@helsinki.fi 358-947-171-898 University of Helsinki

LGL leukemia is a relatively rare, malignant blood disease of the mature T-cells and, in many cases, it is related to autoimmune diseases such as rheumatoid arthritis. The pathogenetic mechanism of the disease has been unknown and it has previously been unclear if the disease is an overreaction of the normal defense system or a malignant hematological disease.

One of the key symptoms of LGL disease is a low count of white blood cells (neutrophils), which may predispose the patients to life-threatening infections.

It was discovered that patients suffering from LGL leukemia have a mutation in the STAT3 gene in a very restricted SH2 area, which has a key effect on the function of the gene. This is not an inherited gene mutation but a so-called acquired mutation. The cause for the mutation is not known, but probably chronic viral infection or some other long-term antigen exposure can be predisposing factors. The STAT3 gene plays a key role in many cell signaling pathways.

After the finding, the prevalence of the mutation in LGL patients was verified using a larger patient group (77 patients) in cooperation with research groups at the Ohio (Prof. Maciejewski) and Pennsylvania (Prof. Loughran) Universities. It was discovered that 40% of all LGL patients present with the STAT3 mutation.

In the future, this result can be utilized in diagnosing the disease and possibly also in treatment, since the first STAT3 inhibitors are already undergoing early clinical trials. In addition, the research discovered that those LGL patients who had a mutation in the STAT3 gene were also more likely to suffer from rheumatoid arthritis. Hence, the research group intends to clarify next if patients suffering from rheumatoid arthritis can be found with similar gene mutations. If such mutations were to be found this would introduce new opportunities to the pathogenetic mechanisms of rheumatoid arthritis and other autoimmune diseases.

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read more from the original source:

Finnish researchers identified the cause for LGL leukemia

Press Release

Foundation Medicine Inc.Posted on:17 May 12

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that new clinical data highlighting the companys comprehensive cancer genomic profile and next-generation sequencing approach in clinical oncology will be presented at the 2012 Annual Meeting of the American Society for Clinical Oncology (ASCO) being held June 1-5, 2012 in Chicago.

The data to be presented at ASCO support Foundation Medicines deep sequencing approach to simultaneously detect all classes of genomic alterations across hundreds of genes known to be related to cancer, said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. In our clinical experience abstract, this approach detected actionable alterations those associated with available targeted treatments or ongoing clinical trials for 74% of tumor samples in the study. Foundation Medicines test has also been shown to identify novel genomic alterations in multiple tumor types, including potentially druggable gene fusions. The combined evidence presented in these studies suggests that fully informative genomic profiling can now become a routine component of cancer patient care.

The schedule for Foundation Medicines oral presentation is as follows:

Date & Time:

Session:

Abstract Number:

Title:

Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens.

Location:

Go here to see the original:

Press Release

Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine'

Newswise New Brunswick, N.J., May 15, 2012 With recent advancements in technology and biomedical informatics, a more personalized approach to prescribing cancer treatment and developing these therapies is preferred over one-size-fits-all methods. The Cancer Institute of New Jersey (CINJ) has been on the cutting-edge of this movement and is now launching a more concrete effort that is poised to change the way that molecular and genetic information is being used to diagnose and treat cancer an initiative known as precision medicine also known to many as personalized medicine. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.

Research has shown that cancer is not one disease, but rather a collection of diseases. Each cancer sub-type boasts its own individual molecular makeup, which in many cases results in cancer growth and resistance to cancer-killing drugs. By further defining the molecular profile of various cancer subtypes, investigators hope to apply this information toward developing targeted therapies. Large scale efforts on the national and local levels including those at CINJ have been underway to collect correlating clinical and genomic data to use as a road map in determining diagnosis, prognosis and course of treatment. With CINJs newly-established precision medicine initiative, specialized investigators will further integrate that information using state-of-the-art technology to better catalogue and expedite the flow of data from researcher to doctor to patient and in turn back to the researcher.

Leading CINJs initiative for precision medicine is Lorna Rodriguez, MD, PhD, who served as CINJs chief of gynecologic oncology from 2000 until this year before being asked to take on this new role. Dr. Rodriguez has years of experience running her own investigator-initiated clinical trials including research on cancer metastasis, drug resistance and the CD44 cell surface receptor and the role it plays in ovarian cancer metastasis. She feels the impact of precision medicine both on patients and on the health/biomedical communities will be tremendous. For the most part, clinicians are forced to rely on limited information to make treatment decisions, as there hasnt been a mechanism to collect and catalogue such comprehensive data as tissue samples, patient history and treatment records to create the tumor profiles necessary for more personalized treatments, noted Rodriguez, who is also a professor of obstetrics, gynecology and reproductive sciences at UMDNJ-Robert Wood Johnson Medical School. By compiling and further curating a collection of molecular and genetic data that will help drive new targeted therapies, we will be helping patients better manage their disease.

This also will translate into cost savings, as no longer will doctors need to rely on hit-or-miss medicine, continued Rodriguez, who also performs gynecologic cancer surgeries and helps patients navigate chemotherapy options. Currently, if one treatment is found to be ineffective, others are used -- and they come at a cost, both financially and in terms of lost time when the patient might have received effective treatment. With the prospects of precision medicine, we are moving closer to an era where we will be able to tailor cancer treatments to perfectly fit individualized patient profiles. This will also lead us to a better understanding in diagnosing disease and providing a prognosis.

The breast cancer drug trastuzumab is one example of how genomic information is helping to drive targeted cancer therapies. Study has shown that trastuzumab is effective for 20 percent of breast cancer patients whose cancer cells make too much of the HER2-positive protein. Because a genetic test can indicate whether a patient has the HER2-positive profile, doctors can better determine whether trastuzumab might be an effective treatment for them.

About The Cancer Institute of New Jersey The Cancer Institute of New Jersey (www.cinj.org) is the states first and only National Cancer Institute-designated Comprehensive Cancer Center dedicated to improving the detection, treatment and care of patients with cancer, and serving as an education resource for cancer prevention. CINJs physician-scientists engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life. To make a tax-deductible gift to support CINJ, call 732-235-8614 or visit http://www.cinjfoundation.org. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. Follow us on Facebook at http://www.facebook.com/TheCINJ.

The CINJ Network is comprised of hospitals throughout the state and provides the highest quality cancer care and rapid dissemination of important discoveries into the community. Flagship Hospital: Robert Wood Johnson University Hospital. System Partner: Meridian Health (Jersey Shore University Medical Center, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, and Bayshore Community Hospital). Major Clinical Research Affiliate Hospitals: Carol G. Simon Cancer Center at Morristown Medical Center, Carol G. Simon Cancer Center at Overlook Medical Center, and Cooper University Hospital. Affiliate Hospitals: CentraState Healthcare System, JFK Medical Center, Robert Wood Johnson University Hospital Hamilton (CINJ Hamilton), Somerset Medical Center, The University Hospital/UMDNJ-New Jersey Medical School*, and University Medical Center at Princeton. *Academic Affiliate

###

View original post here:

Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine'

CNIO scientists successfully test the first gene therapy against aging-associated decline

Public release date: 14-May-2012 [ | E-mail | Share ]

Contact: Juan J. Gomez juanj.gomez@cnio.es 34-917-328-000-4060 Centro Nacional de Investigaciones Oncologicas (CNIO)

A number of studies have shown that it is possible to lengthen the average life of individuals of many species, including mammals, by acting on specific genes. To date, however, this has meant altering the animals' genes permanently from the embryonic stage an approach impracticable in humans. Researchers at the Spanish National Cancer Research Centre (CNIO), led by its director Mara Blasco, have proved that mouse lifespan can be extended by the application in adult life of a single treatment acting directly on the animal's genes. And they have done so using gene therapy, a strategy never before employed to combat ageing. The therapy has been found to be safe and effective in mice.

The results are published today in the journal EMBO Molecular Medicine. The CNIO team, in collaboration with Eduard Ayuso and Ftima Bosch of the Centre of Animal Biotechnology and Gene Therapy at the Universitat Autnoma de Barcelona (UAB), treated adult (one-year-old) and aged (two-year-old) mice, with the gene therapy delivering a "rejuvenating" effect in both cases, according to the authors.

Mice treated at the age of one lived longer by 24% on average, and those treated at the age of two, by 13%. The therapy, furthermore, produced an appreciable improvement in the animals' health, delaying the onset of age-related diseases like osteoporosis and insulin resistance and achieving improved readings on ageing indicators like neuromuscular coordination.

The gene therapy utilised consisted of treating the animals with a DNA-modified virus, the viral genes having been replaced by those of the telomerase enzyme, with a key role in ageing. Telomerase repairs the extremes of chromosomes, known as telomeres, and in doing so slows the cell's and therefore the body's biological clock. When the animal is infected, the virus acts as a vehicle depositing the telomerase gene in the cells.

This study "shows that it is possible to develop a telomerase-based anti-ageing gene therapy without increasing the incidence of cancer", the authors affirm. "Aged organisms accumulate damage in their DNA due to telomere shortening, [this study] finds that a gene therapy based on telomerase production can repair or delay this kind of damage", they add.

'Resetting' the biological clock

Telomeres are the caps that protect the end of chromosomes, but they cannot do so indefinitely: each time the cell divides the telomeres get shorter, until they are so short that they lose all functionality. The cell, as a result, stops dividing and ages or dies. Telomerase gets round this by preventing telomeres from shortening or even rebuilding them. What it does, in essence, is stop or reset the cell's biological clock.

But in most cells the telomerase gene is only active before birth; the cells of an adult organism, with few exceptions, have no telomerase. The exceptions in question are adult stem cells and cancer cells, which divide limitlessly and are therefore immortal in fact several studies have shown that telomerase expression is the key to the immortality of tumour cells.

See the original post:

CNIO scientists successfully test the first gene therapy against aging-associated decline

Pair of molecular biologists receive Albany Medical Center Prize

By Record Staff newsroom@troyrecord.com Twitter.com/troyrecord

Molecular biologist Robert Roeder, left, and James Darnell Jr., right, will share the $500,000 Albany Medical Center Prize in Medicine and Biomedical Research for their pioneering research on how cells express their genetic information. (AP Photo)

ALBANY Two molecular biologists who performed pioneering research on how cells express their genetic information were awarded the annual Albany Medical Center Prize in Medicine and Biomedical Research.

James E. Darnell Jr. and Robert G. Roeder will share $500,000, the largest award in medicine and science in the United States. The prize was established in 2000 by the late Morris "Marty" Silverman, a New York City businessman who wanted to encourage health and biomedical research.

Darnell discovered "RNA processing" in human cells at the Massachusetts Institute in 1963 while studying messenger RNA, which is the template for protein synthesis. Roeder broke ground in the field of gene transcription in animal cells as a University of Washington graduate student in 1969.

"By helping to define how cells grow, replicate, and become specialized, these two scientists have allowed countless other scientists and physicians to explore new ways to fight disease including viruses, heart disease, anemia and autoimmune disorders," James J. Barba, president and chief executive officer of Albany Medical Center, said in March with the award was announced.

Roeder heads the biochemistry and molecular biology lab at The Rockefeller University in New York City, where Darnell is emeritus faculty.

Originally posted here:

Pair of molecular biologists receive Albany Medical Center Prize

Two Molecular Biologists Get $500K Medical Prize

ALBANY, N.Y. (AP) Twomolecularbiologistsare being awarded the annual AlbanyMedicalCenterPrizein Medicine and Biomedical Research.

James Darnell Jr. and Robert Roeder will receive theprizeduring a ceremony Friday and will share $500,000, the largest award in medicine and science in the United States. The two men performed pioneering research on how cells express their genetic information.

Roeder heads the biochemistry andmolecularbiology lab at The Rockefeller University in New York City, where Darnell is emeritus faculty.

The two winners were announced in March.

See the original post:

Two Molecular Biologists Get $500K Medical Prize

2 molecular biologists from NYC to share $500K medical prize for pioneering research on cells

The Canadian Press - ONLINE EDITION

By: The Associated Press

11/05/2012 1:10 PM | Comments: 0

Enlarge Image

Molecular biologist James Darnell Jr., speaks after being awarded the Albany Medical Center Prize in Medicine and Biomedical Research in Albany, N.Y., on Friday, May 11, 2012. Darnell shares the $500,000 prize with Robert Roeder for their pioneering research on how cells express their genetic information. (AP Photo/Mike Groll)

ALBANY, N.Y. - Two molecular biologists have been awarded the annual Albany Medical Center Prize in Medicine and Biomedical Research.

James Darnell Jr. and Robert Roeder received the prize during a ceremony Friday and will share $500,000, the largest award in medicine and science in the United States. The two men performed pioneering research on how cells express their genetic information.

Roeder heads the biochemistry and molecular biology lab at The Rockefeller University in New York City, where Darnell is emeritus faculty.

The two winners were announced in March.

More here:

2 molecular biologists from NYC to share $500K medical prize for pioneering research on cells

Lab21 Unveils New Molecular Analysis Services at Greenville Site

CAMBRIDGE, England--(BUSINESS WIRE)--

Lab21, the global specialist in personalized medicine and clinical diagnostics, is pleased to announce that routine analysis of clinical samples has begun from Lab21 Inc.s new CLIA laboratory in Greenville, South Carolina.

The first assays in the test menu include a new Human Papillomavirus (HPV) High Risk and HPV 16 and 18 Genotyping Service. Using the Roche COBAS 4800 HPV Genotyping test, Lab21 can identify high risk patients and differentiate those patients with HPV 16 and HPV 18 Genotypes. The Lab21 service launches concurrently with new guidelines for the prevention and early detection of cervical cancer which were recently issued by the American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP).

Michael Bolick, President, Lab21 Inc said Over recent months we have grown the Greenville team and worked closely with local clinicians to prioritize the menu of tests required by local hospitals. The final validation of these assays and the receipt of our first patient samples are the culmination of Lab21s strong team work internationally. Our colleagues from the UK have developed best practices in molecular diagnostic testing that we have transferred, along with key individuals, into our US operations.

Lab21 Inc is focused on the provision of molecular diagnostic testing services in oncology and infectious disease. Launch of these services will include KRAS, EGFR and BRAF mutation analysis, HIV viral resistance and tropism and viral load assays. This follows Lab21s recent launch of the Clinical Genomics Center at ITOR, a hospital based cancer research organization located in Greenville, South Carolina. It is planned that through the partnership with ITOR, Lab21 will develop new companion diagnostic assays required to accompany new drug therapies.

Ken Morgan, Vice President Operations, Lab21 Inc said We welcome our new Laboratory Manager, Susan Foster, and Clinical Sequencing Group Leader, Jeremy Stuart to Lab21 Inc who are two very experienced clinical testing professionals from market leading companies. During the next 12 months we intend to grow our core team in Greenville rapidly as we add new test menu and launch our own companion diagnostic assays.

END

About Lab21

Lab21 is a global leader in personalized healthcare. It provides diagnostic products and services and supports blood bank screening, medical diagnostics and drug discovery. Lab21 customers include international healthcare providers, pharmaceutical and diagnostic companies. The Products division of Lab21 manufactures immunodiagnostic kits and reagents that are distributed internationally and is focused on infectious diseases for the blood-banking and clinical markets. Our clinical services operations have a growing test portfolio providing companion diagnostics and high technology molecular assays. Lab21's corporate offices are based in Cambridge, UK and Greenville, South Carolina, with a GMP manufacturing site in Cambridge and other manufacturing facilities in Newmarket, Camberley, Manchester and Bridport. Website: http://www.lab21.com

About the new guidelines for the prevention and early detection of cervical cancer

Link:

Lab21 Unveils New Molecular Analysis Services at Greenville Site

2 molecular biologists share $500K medical prize

Home : Health : 2 molecular biologists share $500K medical prize

The Associated Press

Date: Friday May. 11, 2012 8:14 AM ET

ALBANY, N.Y. Two molecular biologists are being awarded the annual Albany Medical Center Prize in Medicine and Biomedical Research.

James Darnell Jr. and Robert Roeder will receive the prize during a ceremony Friday and will share $500,000, the largest award in medicine and science in the United States. The two men performed pioneering research on how cells express their genetic information.

Roeder heads the biochemistry and molecular biology lab at The Rockefeller University in New York City, where Darnell is emeritus faculty.

The two winners were announced in March.

Share with your social Network:

Read more:

2 molecular biologists share $500K medical prize

Genomics used to identify a molecular-based treatment for a viral skin cancer

ScienceDaily (May 9, 2012) Four years after they discovered the viral roots of a rare skin cancer, researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have now identified a molecule activated by this virus that, in animal studies, could be targeted to selectively kill the tumor cells. The treatment will soon be tested in patients.

Merkel cell carcinoma (MCC), a skin cancer that is more common among seniors and those with weakened immune systems, could not be readily diagnosed at one time, and it still has a very poor prognosis, said Patrick S. Moore, M.D., M.P.H., and Yuan Chang, M.D., both of the Cancer Virology Program at UPCI and senior authors of a study that appears online May 9 in Science Translational Medicine.

"This research effort shows the speed at which genomics can identify molecular causes for cancer and then point the way toward a rational and targeted treatment," Dr. Moore noted. "Since the inception of the 1971 U.S. National Cancer Act, researchers have strived to discover the underlying problems that trigger tumor development."

In 2008, the team first described the new Merkel cell polyomavirus (MCV) in Merkel cell carcinoma. Within a year, they showed it was responsible for tumor development in most cases of the disease. At least four out of five healthy adults world-wide are infected with MCV, which usually doesn't cause any symptoms.

"The virus remains in the skin cells, and in most cases, no damage is done," Dr. Chang said. "But when mutations occur to this virus, it can cause cancer. Most of the 1,500 new MCC cases per year in the U.S. are caused by MCV infection."

In quick succession, the team devised tests to identify virus-induced MCC, and began unraveling the biochemical pathways that encourage tumor formation. In their latest project, they "knocked out" a key viral protein called T antigen and found that MCV directly elevates a cellular protein called survivin.

Survivin prevents cells from dying and supports cell division, the researchers said. They found that a drug called YM155, which turns off the survivin gene again, was an extremely potent killer of MCC cells in test tubes and was able to suppress the growth of human tumors that had been established in experimental mice. In comparison, 1,360 other drugs -- including most of the common chemotherapy drugs -- were screened and failed to both kill MCC cells and prevent tumor growth at levels commonly achieved in patients. One of these drugs was able to kill tumor cells in culture dishes, but made no impact on the MCC tumors in mice. It remains a promising candidate drug since it may have better activity in people and is readily available.

A multicenter clinical trial of YM155, a still-experimental anti-cancer drug that is made by Deerfield, Ill.-based Astellas, is expected to begin in the next six months to determine its effectiveness in MCC patients. The trial will be led locally by Pitt School of Medicine assistant professor Hussein Tawbi, M.D., Ph.D., and professor John Kirkwood, M.D., who also is co-leader of the UPCI Melanoma Program, through the Eastern Cooperative Oncology Group, a multicenter cooperative group supported by the National Cancer Institute (NCI), part of the National Institutes of Health.

Typically, neither the cause of a cancer nor the target for a cancer drug is initially known, so most treatments have developed over decades through trial-and-error. Most therapies affect both healthy tissues and cancer cells, resulting in side effects that limit the drug dose that can safely be given. This study, in contrast, was a "rational" drug study where the underlying cellular defect caused by the virus was first discovered through genetic studies and then a drug targeting this process was tested.Survivin is needed during fetal development, but not in healthy adult cells, and YM155 was not toxic to the mice.

"Scientists can now quickly come up with answers to complex problems, like cancer, using human genetics," Dr. Moore noted. "In less than five years, we have gone from knowing very little about MCC to knowing its exact cause and are devising new, precisely targeted and less-toxic therapies."

Original post:

Genomics used to identify a molecular-based treatment for a viral skin cancer

Pitt team uses genomics to identify a molecular-based treatment for a viral skin cancer

Public release date: 9-May-2012 [ | E-mail | Share ]

Contact: Anita Srikameswaran SrikamAV@upmc.edu 412-578-9193 University of Pittsburgh Schools of the Health Sciences

PITTSBURGH, May 9 Four years after they discovered the viral roots of a rare skin cancer, researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have now identified a molecule activated by this virus that, in animal studies, could be targeted to selectively kill the tumor cells. The treatment will soon be tested in patients.

Merkel cell carcinoma (MCC), a skin cancer that is more common among seniors and those with weakened immune systems, could not be readily diagnosed at one time, and it still has a very poor prognosis, said Patrick S. Moore, M.D., M.P.H., and Yuan Chang, M.D., both of the Cancer Virology Program at UPCI and senior authors of a study that appears online today in Science Translational Medicine.

"This research effort shows the speed at which genomics can identify molecular causes for cancer and then point the way toward a rational and targeted treatment," Dr. Moore noted. "Since the inception of the 1971 U.S. National Cancer Act, researchers have strived to discover the underlying problems that trigger tumor development."

In 2008, the team first described the new Merkel cell polyomavirus (MCV) in Merkel cell carcinoma. Within a year, they showed it was responsible for tumor development in most cases of the disease. At least four out of five healthy adults world-wide are infected with MCV, which usually doesn't cause any symptoms.

"The virus remains in the skin cells, and in most cases, no damage is done," Dr. Chang said. "But when mutations occur to this virus, it can cause cancer. Most of the 1,500 new MCC cases per year in the U.S. are caused by MCV infection."

In quick succession, the team devised tests to identify virus-induced MCC, and began unraveling the biochemical pathways that encourage tumor formation. In their latest project, they "knocked out" a key viral protein called T antigen and found that MCV directly elevates a cellular protein called survivin.

Survivin prevents cells from dying and supports cell division, the researchers said. They found that a drug called YM155, which turns off the survivin gene again, was an extremely potent killer of MCC cells in test tubes and was able to suppress the growth of human tumors that had been established in experimental mice. In comparison, 1,360 other drugsincluding most of the common chemotherapy drugswere screened and failed to both kill MCC cells and prevent tumor growth at levels commonly achieved in patients. One of these drugs was able to kill tumor cells in culture dishes, but made no impact on the MCC tumors in mice. It remains a promising candidate drug since it may have better activity in people and is readily available.

A multicenter clinical trial of YM155, a still-experimental anti-cancer drug that is made by Deerfield, Ill.-based Astellas, is expected to begin in the next six months to determine its effectiveness in MCC patients. The trial will be led locally by Pitt School of Medicine assistant professor Hussein Tawbi, M.D., Ph.D., and professor John Kirkwood, M.D., who also is co-leader of the UPCI Melanoma Program, through the Eastern Cooperative Oncology Group, a multicenter cooperative group supported by the National Cancer Institute (NCI), part of the National Institutes of Health.

Read the original here:

Pitt team uses genomics to identify a molecular-based treatment for a viral skin cancer

In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers …

NEW YORK, May 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0849772/In-Vitro-Diagnostics-IVD-Market-Clinical-Chemistry-Immunoassays-Molecular-Diagnostics-Hematology-Analyzers--Microbiology-Culture--Global-Trends--Forecasts-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) Global Trends & Forecasts to 2016

The global in-vitro diagnostics (IVD) market was valued at $44 billion in 2011 and is expected to have a modest growth during the study period. The U.S. represented the biggest market for IVD equipments accounting for about a half of the total market. The report studies various segments of the IVD market including Clinical Chemistry, Molecular diagnostics, Immunoassays, Hematology and Microbiology. Clinical chemistry dominates the global IVD market whereas molecular diagnostics is expected to register the highest growth during the study period. Increased patient awareness, patient self testing, rapidly aging population globally and automated testing due to technical advances are the major growth drivers of this market. Key players in the IVD market include Roche Diagnostics, Abbott Diagnostics, Beckman Coulter, BD Diagnostics, and Siemens Diagnostics.

1.1 KEY TAKE-AWAYS

1.2 REPORT DESCRIPTION

1.3 MARKETS COVERED

1.4 STAKEHOLDERS

1.5 RESEARCH METHODOLOGY

1.5.1 MARKET SIZE

View post:

In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers ...